Mavrilimumab for severe COVID-19

Khan, Ajmal; Soneja, Manish; Tirlangi, Praveen; Wig, Naveet

doi:10.1016/s2665-9913(20)30306-4

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, their underlying pharmacological mechanisms, safety, and adverse events in the treatment of COVID-19 have not been clearly clarified. In addition, the safety and efficacy of GM-CSF antibodies in the treatment of COVID-19 are also controversial; in particular, mortality, drug use, and secondary infections should be of concern [4][5][6] . Therefore, the present meta-analysis was conducted to investigate GM-CSF antibody treatment in COVID-19 patients.…”

Section: Introductionmentioning

confidence: 99%

Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis

Guan

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: We performed a meta analysis in order to determine safety of granulocyte macrophage colony stimulating factor (GM CSF) antibodies on COVID 19. Methods: We searched from the Cochrane Library, PubMed, Embase, biorxiv and medrxiv databases beginning in the COVID-19 outbreak on December 1, 2019 until August 29, 2021. The primary outcomes included death, the incidence of invasive mechanical ventilation (IMV), ventilation requirement, and secondary infection. Results: 6 eligible literature involving 1501 COVID 19 patients were recruited, and they were divided into experimental group (n = 736) and control group (n = 765). Using a random effect model, we found that the GM CSF antibodies treatment was associated with a 3.8-26.9% decline of the risk of mortality[odd ratio (OR) = 0.06, 95% confidence interval (CI): -0.11, -0.01, p =0.02], a 5.3-28.7% reduction of incidence of IMV [OR = 0.51, 95% CI: 0.28, 0.95, p =0.03], and a 23.3-50.0% enhancement of ventilation improvement [OR = 11.70, 95% CI: 1.99, 68.68, p=0.006]. There were no statistically significant differences in the association between two groups in second infection. Conclusion: Severe COVID 19 patients may benefit from GM CSF antibodies.

show abstract

Section: Introductionmentioning

confidence: 99%

Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis

Guan

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Antagonizing the GM-CSF receptor or directly binding circulating GM-CSF may be beneficial for treating hyperinflammation-related lung injury (Bonaventura et al 2020 ; Lang et al 2020 ; Sterner et al 2019 ). However, the efficacy and safety of GM-CSF antibodies in the treatment of COVID-19 have not been clarified (Khan et al 2020 ; Rizk et al 2020 ). Therefore, the present meta-analysis was conducted to investigate the effects of GM-CSF antibody treatment in COVID-19 patients.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of granulocyte–macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis

Luo

Guan

et al. 2022

Inflammopharmacol

View full text Add to dashboard Cite

Objective This study aims to determine the efficacy and safety of granulocyte–macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients. Methods We searched Cochrane Library, PubMed, Embase, and ClinicalTrials.gov databases until July 27, 2022. Both randomized control trials (RCTs) and cohort studies were included and analyzed separately. The outcomes included mortality, incidence of invasive mechanical ventilation (IMV), ventilation improvement rate (need oxygen therapy to without oxygen therapy), secondary infection, and adverse events (AEs). The odds ratio (OR) with a 95% confidence interval (CI) was calculated by a random-effects meta-analysis model. Results Five RCTs and 2 cohort studies with 1726 COVID-19 patients were recruited ( n = 866 in the GM-CSF antibody group and n = 891 in the control group). GM-CSF antibodies treatment reduced the incidence of IMV, which was supported by two cohort studies (OR 0.16; 95% CI 0.03, 0.74) and three RCTs (OR 0.62; 95% CI 0.41, 0.94). GM-CSF antibodies resulted in slight but not significant reductions in mortality (based on two cohort studies and five RCTs) and ventilation improvement (based on one cohort study and two RCTs). The sensitive analysis further showed the results of mortality and ventilation improvement rate became statistically significant when one included study was removed. Besides, GM-CSF antibodies did not increase the risks of the second infection (based on one cohort study and five RCTs) and AEs (based on five RCTs). Conclusion GM-CSF antibody treatments may be an efficacious and well-tolerant way for the treatment of COVID-19. Further clinical evidence is still warranted. Supplementary Information The online version contains supplementary material available at 10.1007/s10787-022-01105-9.

show abstract

Mavrilimumab for severe COVID-19

Cited by 2 publications

References 3 publications

Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis

Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis

Efficacy and safety of granulocyte–macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis

Contact Info

Product

Resources

About